Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature

References

• World Health OrganizationDepression. Fact sheet No. 369102012 Available from: www.cho.int/mediacentre/factsheets/fs369/en/Accessed July 21, 2015
   Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, Fifth EditionWashington, DC, USAAmerican Psychiatric Publishing2013
   Google Scholar
• World Health OrganizationPromoting mental health: concepts, emerging evidence, practice (summary report)Geneva, SwitzerlandWorld Health Organization2004 Available from: http://www.who.int/mental_health/evidence/en/promoting_mhh.pdfAccessed July 22, 2015
   Google Scholar
• FerrariAJCharlsonFJNormanREBurden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease Study 2010PLoS Med201310e100154724223526
   PubMed Web of Science ®Google Scholar
• World Health Organization and Department of Mental Health and Substance AbuseVictorian Health Promotion FoundationUniversity of MelbournePromoting mental health: concepts, emerging evidence, practice: summary reportGeneva, SwitzerlandWorld Health Organization2004 Available from: http://www.who.int/mental_health/evidence/en/promoting_mhh.pdfAccessed July 22, 2015
   Google Scholar
• StegengaBTKamphuisMHKingMNazarethIGeerlingsMIThe natural course and outcome of major depressive disorder in primary care: the PREDICT-NL studySoc Psychiatry Psychiatr Epidemiol201247879521057769
   PubMed Web of Science ®Google Scholar
• EatonWWShaoHNestadtGLeeHBBienvenuOJZandiPPopulation-based study of first onset and chronicity in major depressive disorderArch Gen Psychiatry20086551352018458203
   PubMed Web of Science ®Google Scholar
• CoryellWAkiskalHSLeonACThe time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression – clinical studiesArch Gen Psychiatry1994514054108179464
   PubMed Web of Science ®Google Scholar
• MannJJThe medical management of depressionN Engl J Med20053531819183416251538
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical ExcellenceDepression: management of depression in primary and secondary care. Clinical Guideline 23London, UKNational Institute for Clinical Excellence2004 Available from: https://www.nice.org.uk/guidance/cg023Accessed July 22, 2015
   Google Scholar
• PapakostasGIFavaMDoes the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDDEur Neuropsychopharmacol200919344018823760
   PubMed Web of Science ®Google Scholar
• SheltonRCTreatment options for refractory depressionJ Clin Psychiatry199960Suppl 4576110086483
   PubMed Web of Science ®Google Scholar
• KellerMBPast, present, and future directions for defining optimal treatment outcome in depression: remission and beyondJAMA20032893152316012813121
   PubMed Web of Science ®Google Scholar
• MachadoMIskedjianMRuizIEinarsonTRRemission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trialsCurr Med Res Opin2006221825183716968586
   PubMed Web of Science ®Google Scholar
• TrivediMHRushAJWisniewskiSREvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry2006163284016390886
   PubMed Web of Science ®Google Scholar
• RushAJTrivediMHWisniewskiSRAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportAm J Psychiatry20061631905191717074942
   PubMed Web of Science ®Google Scholar
• ThaseMEFriedmanESBiggsMMCognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D reportAm J Psychiatry200716473975217475733
   PubMed Web of Science ®Google Scholar
• ThaseMERushAJWhen at first you don’t succeed: sequential strategies for antidepressant nonrespondersJ Clin Psychiatry199758Suppl 1323299402916
   PubMed Web of Science ®Google Scholar
• TrivediMHFavaMWisniewskiSRMedication augmentation after the failure of SSRIs for depressionN Engl J Med20063541243125216554526
   PubMed Web of Science ®Google Scholar
• PapakostasGISheltonRCSmithJFavaMAugmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysisJ Clin Psychiatry20076882683117592905
   PubMed Web of Science ®Google Scholar
• Vortioxetine Hydrobromide [database on the Internet]National Center for Biotechnology Information. PubChem Available from: http://pubchem.ncbi.nlm.nih.gov/compound/Vortioxetine_hydrobromideAccessed December 30, 2014
   Google Scholar
• JansLARiedelWJMarkusCRBloklandASerotonergic vulnerability and depression: assumptions, experimental evidence and implicationsMol Psychiatry20071252254317160067
   PubMed Web of Science ®Google Scholar
• SchildkrautJJThe catecholamine hypothesis of affective disorders: a review of supporting evidenceAm J Psychiatry19651225095225319766
   PubMed Web of Science ®Google Scholar
• ElhwuegiASCentral monoamines and their role in major depressionProg Neuropsychopharmacol Biol Psychiatry20042843545115093950
   PubMed Web of Science ®Google Scholar
• Bang-AndersenBRuhlandTJorgensenMDiscovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorderJ Med Chem2011543206322121486038
   PubMed Web of Science ®Google Scholar
• ArenbergJLuntang-JensenMSogaardBNilausenDOOccupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjectsBasic Clin Pharmacol Toxicol201111040140421985522
   PubMed Web of Science ®Google Scholar
• RichelsonEInteractions of antidepressants with neurotransmitter transporters and receptors and their clinical relevanceJ Clin Psychiatry200364Suppl 1351214552650
   PubMed Web of Science ®Google Scholar
• SanchezCAsinKEArtigasFVortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical dataPharmacol Ther2015145435725016186
   PubMed Web of Science ®Google Scholar
• MorkAPehrsonABrennumLTPharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorderJ Pharmacol Exp Ther201234066667522171087
   PubMed Web of Science ®Google Scholar
• ArtigasFAdellACeladaPPindolol augmentation of antidepressant responseCurr Drug Targets2006713914716475955
   PubMed Web of Science ®Google Scholar
• CarrGVLuckiIThe role of serotonin receptor subtypes in treating depression: a review of animal studiesPsychopharmacology (Berl)201121326528721107537
   PubMed Web of Science ®Google Scholar
• StahlSMMechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effectsJ Affect Disord19985121523510333979
   PubMed Web of Science ®Google Scholar
• PullarIABootJRBroadmoreRJThe role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pigEur J Pharmacol2004493859315189767
   PubMed Web of Science ®Google Scholar
• BonaventurePDugovicCKramerMTranslational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorderJ Pharmacol Exp Ther201234242944022570363
   PubMed Web of Science ®Google Scholar
• PehrsonALCremersTBetryCLu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters – a rat microdialysis and electrophysiology studyEur Neuropsychopharmacol20132313314522612991
   PubMed Web of Science ®Google Scholar
• BlierPWardNMIs there a role for 5-HT1A agonists in the treatment of depression?Biol Psychiatry20035319320312559651
   PubMed Web of Science ®Google Scholar
• BlierPEl MansariMSerotonin and beyond: therapeutics for major depressionPhilos Trans R Soc Lond B Biol Sci20133682012053623440470
   PubMed Web of Science ®Google Scholar
• GriebelGHolmesA50 years of hurdles and hope in anxiolytic drug discoveryNat Rev Drug Discov20131266768723989795
   PubMed Web of Science ®Google Scholar
• KishiTMeltzerHYMatsudaYIwataNAzapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysisPsychol Med2014442255226924262766
   PubMed Web of Science ®Google Scholar
• PortellaMJde Diego-AdelinoJBallesterosJCan we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depressionJ Clin Psychiatry20117296296921034693
   PubMed Web of Science ®Google Scholar
• BermanRMAnandACappielloAThe use of pindolol with flu-oxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trialBiol Psychiatry1999451170117710331109
   PubMed Web of Science ®Google Scholar
• BermanRMDarnellAMMillerHLAnandACharneyDSEffect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trialAm J Psychiatry199715437438988956
   PubMed Web of Science ®Google Scholar
• PerezVSolerJPuigdemontDAlvarezEArtigasFA double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns AfectiusArch Gen Psychiatry19995637537910197835
   PubMed Web of Science ®Google Scholar
• PerryEBBermanRMSanacoraGAnandALynch-ColoneseKCharneyDSPindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trialJ Clin Psychiatry20046523824315003079
   PubMed Web of Science ®Google Scholar
• Brintellix (vortioxetine) package insertDeerfield, IL, USATakeda Pharmaceuticals America, Inc2014
   Google Scholar
• PearceEFMurphyJAVortioxetine for the treatment of depressionAnn Pharmacother20144875876524676550
   PubMed Web of Science ®Google Scholar
• HvenegaardMGBang-AndersenBPedersenHJorgensenMPuschlADalgaardLIdentification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004Drug Metab Dispos2012401357136522496396
   PubMed Web of Science ®Google Scholar
• ChenGLeeRHojerAMBuchbjergJKSerenkoMZhaoZPharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressantClin Drug Investig201333727736
   PubMed Web of Science ®Google Scholar
• AlvarezEPerezVDragheimMLoftHArtigasFA double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInt J Neuropsychopharmacol20121558960021767441
   PubMed Web of Science ®Google Scholar
• HenigsbergNMahableshwarkarARJacobsenPChenYThaseMEA randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorderJ Clin Psychiatry20127395395922901346
   PubMed Web of Science ®Google Scholar
• KatonaCHansenTOlsenCKA randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorderInt Clin Psychopharmacol20122721522322572889
   PubMed Web of Science ®Google Scholar
• JainRMahableshwarkarARJacobsenPLChenYThaseMEA randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorderInt J Neuropsychopharmacol20131631332122963932
   PubMed Web of Science ®Google Scholar
• MahableshwarkarARJacobsenPLChenYA randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorderCurr Med Res Opin20132921722623252878
   PubMed Web of Science ®Google Scholar
• BoulengerJPLoftHOlsenCKEfficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorderInt Clin Psychopharmacol20142913814924257717
   PubMed Web of Science ®Google Scholar
• McIntyreRSLophavenSOlsenCKA randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adultsInt J Neuropsychopharmacol2014171557156724787143
   PubMed Web of Science ®Google Scholar
• MontgomerySANielsenRZPoulsenLHHaggstromLA randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatineHum Psychopharmacol20142947048225087600
   PubMed Web of Science ®Google Scholar
• BaldwinDSLoftHDragheimMA randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)Eur Neuropsychopharmacol20122248249122209361
   PubMed Web of Science ®Google Scholar
• JacobsenPLMahableshwarkarARSerenkoMChanSTrivediMHA randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorderJ Clin Psychiatry20157657558226035185
   PubMed Web of Science ®Google Scholar
• MahableshwarkarARJacobsenPLSerenkoMChenYTrivediMHA randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorderJ Clin Psychiatry20157658359126035186
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• BerhanABarkerAVortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trialsBMC Psychiatry20141427625260373
   PubMed Web of Science ®Google Scholar
• PaeCUWangSMHanCVortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorderJ Psychiatry Neurosci20154017418625350320
   PubMed Web of Science ®Google Scholar
• CitromeLVortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract201468608224165478
   PubMed Web of Science ®Google Scholar
• LlorcaPMLanconCBrignoneMRelative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studiesCurr Med Res Opin2014302589260625249164
   PubMed Web of Science ®Google Scholar
• FuJChenYThe efficacy and safety of 5 mg/d vortioxetine compared to placebo for major depressive disorder: a meta-analysisPsychopharmacology (Berl)201523271624871704
   PubMed Web of Science ®Google Scholar
• BaldwinDSHansenTFloreaIVortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorderCurr Med Res Opin2012281717172422978748
   PubMed Web of Science ®Google Scholar
• AlamMYJacobsenPLChenYSerenkoMMahableshwarkarARSafety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension studyInt Clin Psychopharmacol201429364424169027
   PubMed Web of Science ®Google Scholar
• BoulengerJPLoftHFloreaIA randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorderJ Psychopharmacol2012261408141622495621
   PubMed Web of Science ®Google Scholar
• RosenbergKPBleibergKLKoscisJGrossCA survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on complianceJ Sex Marital Ther20032928929614504017
   PubMed Web of Science ®Google Scholar
• WilliamsVSBaldwinDSHogueSLFehnelSEHollisKAEdinHMEstimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient surveyJ Clin Psychiatry20066720421016566614
   PubMed Web of Science ®Google Scholar
• van GeffenECvan der WalSWvan HultenRde GrootMCEgbertsACHeerdinkEREvaluation of patients’ experiences with antidepressants reported by means of a medicine reporting systemEur J Clin Pharmacol2007631193119917874086
   PubMed Web of Science ®Google Scholar
• McGahueyCAGelenbergAJLaukesCAThe Arizona Sexual Experience Scale (ASEX): reliability and validityJ Sex Marital Ther200026254010693114
   PubMed Web of Science ®Google Scholar
• WarnerCHBoboWWarnerCReidSRachalJAntidepressant discontinuation syndromeAm Fam Physician20067444945616913164
   PubMed Web of Science ®Google Scholar
• ZajeckaJTracyKAMitchellSDiscontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature reviewJ Clin Psychiatry1997582912979269249
   PubMed Web of Science ®Google Scholar
• BlackKSheaCDursunSKutcherSSelective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteriaJ Psychiatry Neurosci20002525526110863885
   PubMed Web of Science ®Google Scholar
• RosenbaumJFFavaMHoogSLAscroftRCKrebsWBSelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trialBiol Psychiatry19984477879646889
   PubMed Web of Science ®Google Scholar
• JacobsenPMahableshwarkarASerenkoMChanSTrivediMEfficacy and safety of vortioxetine 10 mg and 20 mg in an 8-week, randomized, double-blind, placebo-controlled study of adults with major depressive disorder Available from: http://www.psychcongress.com/posters/efficacy-and-safety-vortioxetine-10mg-and-20mg-8-week-randomized-double-blind-placeboAccessed July 22, 2015
   Google Scholar
• MahableshwarkarAJacobsenPSerenkoMChenYTrivediMEfficacy and safety of vortioxetine 15 and 20 mg in an 8-week placebo-controlled and duloxetine-referenced trial of adults with major depressive disorder Available from: http://www.psychcongress.com/posters/efficacy-and-safety-vortioxetine-15-and-20-mg-8-week-placebo-controlled-and-duloxetineAccessed July 22, 2015
   Google Scholar
• ArtigasFNuttDJSheltonRMechanism of action of antidepressantsPsychopharmacol Bull200236Suppl 212313212490828
   PubMedGoogle Scholar
• DawsonLAWatsonJMVilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disordersCNS Neurosci Ther20091510711719499624
   PubMed Web of Science ®Google Scholar
• DuruGFantinoBThe clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approachCurr Med Res Opin2008241329133518377706
   PubMed Web of Science ®Google Scholar
• ZimmermanMChelminskiIPosternakMAGeneralizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trialAm J Psychiatry20051621370137215994721
   PubMed Web of Science ®Google Scholar
• CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisLancet200937374675819185342
   PubMed Web of Science ®Google Scholar
• GirardiPPompiliMInnamoratiMDuloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methodsHum Psychopharmacol20092417719019229839
   PubMed Web of Science ®Google Scholar
• ZhangJMathisMVSellersJWThe US Food and Drug Administration’s perspective on the new antidepressant vortioxetineJ Clin Psychiatry20157681425562777
   PubMed Web of Science ®Google Scholar
• McIntyreRSWhen should you move beyond first-line therapy for depression?J Clin Psychiatry201071Suppl 1162020977871
   PubMedGoogle Scholar
• PapakostasGIThaseMEFavaMNelsonJCSheltonRCAre antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agentsBiol Psychiatry2007621217122717588546
   PubMed Web of Science ®Google Scholar
• BerlimMTTureckiGWhat is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trialsEur Neuropsychopharmacol20071769670717521891
   PubMed Web of Science ®Google Scholar
• AlvarezEPerezVArtigasFPharmacology and clinical potential of vortioxetine in the treatment of major depressive disorderNeuropsychiatr Dis Treat2014101297130725075188
   PubMed Web of Science ®Google Scholar
• BaldwinDSNuttDJOn assessing potential efficacy for vortioxetine in generalized anxiety disorderEur Neuropsychopharmacol20122284184322906521
   PubMed Web of Science ®Google Scholar
• HasinDSGoodwinRDStinsonFSGrantBFEpidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related ConditionsArch Gen Psychiatry2005621097110616203955
   PubMed Web of Science ®Google Scholar
• KesslerRCGruberMHettemaJMHwangISampsonNYonkersKACo-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-upPsychol Med20083836537418047766
   PubMed Web of Science ®Google Scholar
• BidzanLMahableshwarkarARJacobsenPYanMSheehanDVVortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trialEur Neuropsychopharmacol20122284785722898365
   PubMed Web of Science ®Google Scholar
• RothschildAJMahableshwarkarARJacobsenPYanMSheehanDVVortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United StatesEur Neuropsychopharmacol20122285886622901736
   PubMed Web of Science ®Google Scholar
• MahableshwarkarARJacobsenPLSerenkoMChenYA randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorderHum Psychopharmacol201429647224424707
   PubMed Web of Science ®Google Scholar
• TheunissenELStreetDHojerAMVermeerenAvanOARamaekersJGA randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognitionClin Pharmacol Ther20139349350123588319
   PubMed Web of Science ®Google Scholar